Abstract
The B-cell receptor signaling pathway is active in diffuse large B-cell lymphomas, with increased expression of MYC and BCL2 protein.
The overall response rate was 60% for relapsed/refractory non–germinal center double-expressor lymphoma patients treated with ibrutinib.
MeSH terms
-
Adenine / analogs & derivatives
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Biomarkers, Tumor
-
Drug Resistance, Neoplasm
-
Female
-
Genes, bcl-2*
-
Genes, myc*
-
Humans
-
Lymphoma, B-Cell / diagnosis
-
Lymphoma, B-Cell / drug therapy*
-
Lymphoma, B-Cell / genetics*
-
Lymphoma, B-Cell / mortality
-
Male
-
Middle Aged
-
Piperidines
-
Prognosis
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / therapeutic use*
-
Pyrazoles / administration & dosage
-
Pyrazoles / adverse effects
-
Pyrazoles / therapeutic use*
-
Pyrimidines / administration & dosage
-
Pyrimidines / adverse effects
-
Pyrimidines / therapeutic use*
-
Recurrence
-
Retreatment
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Biomarkers, Tumor
-
Piperidines
-
Protein Kinase Inhibitors
-
Pyrazoles
-
Pyrimidines
-
ibrutinib
-
Adenine